Waverly Advisors LLC Buys 270,863 Shares of GSK PLC Sponsored ADR $GSK

Waverly Advisors LLC boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 1,372.8% during the 2nd quarter, Holdings Channel reports. The firm owned 290,593 shares of the pharmaceutical company’s stock after buying an additional 270,863 shares during the quarter. Waverly Advisors LLC’s holdings in GSK were worth $15,233,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in GSK. Elyxium Wealth LLC purchased a new position in shares of GSK during the fourth quarter valued at about $30,000. Triumph Capital Management purchased a new stake in shares of GSK in the third quarter worth about $40,000. Trust Co. of Vermont bought a new position in GSK during the second quarter valued at approximately $54,000. Philadelphia Investment Partners LLC bought a new position in GSK during the second quarter valued at approximately $70,000. Finally, Ancora Advisors LLC bought a new position in GSK during the second quarter valued at approximately $71,000. Institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GSK. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. HSBC raised shares of GSK from a “reduce” rating to a “hold” rating in a report on Monday, July 6th. Jefferies Financial Group upgraded shares of GSK to a “strong-buy” rating in a research report on Friday, July 17th. Finally, Weiss Ratings downgraded shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, GSK currently has an average rating of “Hold” and an average price target of $53.00.

GSK Trading Down 2.6%

GSK opened at $48.57 on Wednesday. The stock has a 50-day moving average of $51.56 and a 200 day moving average of $52.99. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. GSK PLC Sponsored ADR has a 12 month low of $39.29 and a 12 month high of $61.69. The firm has a market cap of $98.24 billion, a P/E ratio of 15.19, a P/E/G ratio of 1.95 and a beta of 0.35.

GSK (NYSE:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%.The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.02 billion. During the same period in the prior year, the business posted $0.47 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, research analysts forecast that GSK PLC Sponsored ADR will post 4.83 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a $0.4515 dividend. This is an increase from GSK’s previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a yield of 3.7%. GSK’s dividend payout ratio is currently 55.63%.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.